Stock Evaluator: Aspire Biopharma Holdings, Inc. (ASBP)
Aspire Biopharma Holdings, Inc. ASBP
$6.52
-0.20
-2.98%
July 31, 2026 4:00:00 PM
EST
Volume: 9,419
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Pharmaceuticals |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Aspire Biopharma Holdings, Inc., an early-stage biopharmaceutical company, develops and markets disruptive technology for novel sublingual delivery mechanisms in the United States. It offers sublingual aspirin product that is a soluble, PH neutral, and fast acting aspirin, which addresses cardiology emergencies and pain management. The company is also developing formulations for sublingually administered products, such as melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide product. In addition, it is developing formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and other classes of drugs through sublingual administration; and caffeine products, such as a formula for a single dose sublingual pre-workout supplement. The company was founded in 2021 and is headquartered in Estero, Florida.
Financial Summary
| Share Statistics | ASBP | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $8.4 | $579.1 | 6% |
|
| Shares Out (Mil) | 0.2 | 43.0 | 1% |
|
| Institutional Ownership | 14.6% | 84.3% | 9% |
|
| Float (Mil) | 1.2 | 46.8 | 3% |
|
| Beta | 0.15 | 0.62 | 10% |
|
| Avg Daily Volume (000s) | 58 | 285 | 30% |
|
| Price Change (52-week) |
(98.7%) | 63.8% | 1% |
|
| Growth | ASBP | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.7% | na |
|
| Net Income (5yr) | na | (1.4%) | na |
|
| EPS (5yr) | na | 14.9% | na |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (14.9%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | ASBP | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $272 | na |
|
| Net Income (TTM) (Mil) | ($12) | ($11) | 28% |
|
| EPS (TTM) | ($145.018) | ($0.500) | 0% |
|
| Operating Cash Flow (TTM) (Mil) | ($6) | ($6) | 23% |
|
| Net Cash Flow (TTM) (Mil) | na | $4 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $7 | 0% |
|
| Enterprise Value (Q1) (Mil) | $4 | $522 | 5% |
|
| Valuation | ASBP | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.28 | 2.73 | 4% |
|
| P/E | na | 20.5 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.2 | na |
|
| Ratios | ASBP | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 16.3% | 65.9% | 16% |
|
| Net Margin | na | 0.7% | na |
|
| ROA | (259.0%) | (24.6%) | 1% |
|
| ROE | 762.7% | (19.7%) | 100% |
|
| Liabilities to Assets | 45.6% | 35.5% | 37% |
|
| F-Score | 2 | 3 | 7% |
|
Aspire Biopharma Holdings, Inc. did not pass any screens on 7/31/2026.
